234 related articles for article (PubMed ID: 37537199)
1. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis.
Ding D; Blee AM; Zhang J; Pan Y; Becker NA; Maher LJ; Jimenez R; Wang L; Huang H
Nat Commun; 2023 Aug; 14(1):4671. PubMed ID: 37537199
[TBL] [Abstract][Full Text] [Related]
2. Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53.
Prowald A; Cronauer MV; von Klot C; Eilers T; Rinnab L; Herrmann T; Spindler KD; Montenarh M; Jonas U; Burchardt M
Prostate; 2007 Dec; 67(16):1751-60. PubMed ID: 17929268
[TBL] [Abstract][Full Text] [Related]
3. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
4. The Expression of Proto-Oncogene
Khosh Kish E; Choudhry M; Gamallat Y; Buharideen SM; D D; Bismar TA
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563163
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.
Ratz L; Laible M; Kacprzyk LA; Wittig-Blaich SM; Tolstov Y; Duensing S; Altevogt P; Klauck SM; Sültmann H
Oncotarget; 2017 Apr; 8(15):25115-25130. PubMed ID: 28445989
[TBL] [Abstract][Full Text] [Related]
6. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
Zoma M; Curti L; Shinde D; Albino D; Mitra A; Sgrignani J; Mapelli SN; Sandrini G; Civenni G; Merulla J; Chiorino G; Kunderfranco P; Cacciatore A; Kokanovic A; Rinaldi A; Cavalli A; Catapano CV; Carbone GM
Nat Commun; 2021 Jul; 12(1):4147. PubMed ID: 34230470
[TBL] [Abstract][Full Text] [Related]
7. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
8. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence.
Fang L; Li D; Yin J; Pan H; Ye H; Bowman J; Capaldo B; Kelly K
Cancer Gene Ther; 2022 Oct; 29(10):1463-1476. PubMed ID: 35393570
[TBL] [Abstract][Full Text] [Related]
10. Plakoglobin restores tumor suppressor activity of p53
Alaee M; Nool K; Pasdar M
Cancer Sci; 2018 Jun; 109(6):1876-1888. PubMed ID: 29660231
[TBL] [Abstract][Full Text] [Related]
11. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
12. TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.
Zhou F; Gao S; Han D; Han W; Chen S; Patalano S; Macoska JA; He HH; Cai C
Oncogene; 2019 May; 38(22):4397-4411. PubMed ID: 30718921
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
14. Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG.
Giannareas N; Zhang Q; Yang X; Na R; Tian Y; Yang Y; Ruan X; Huang D; Yang X; Wang C; Zhang P; Manninen A; Wang L; Wei GH
Nat Commun; 2022 Nov; 13(1):7320. PubMed ID: 36443337
[TBL] [Abstract][Full Text] [Related]
15. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
16. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
17. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.
Raina K; Kant R; Prasad RR; Kandhari K; Tomar M; Mishra N; Kumar R; Fox JT; Sei S; Shoemaker RH; Chen Y; Maroni P; Agarwal C; Agarwal R
Mol Carcinog; 2022 Jul; 61(7):717-734. PubMed ID: 35452553
[TBL] [Abstract][Full Text] [Related]
18. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
19. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
Trifunovski A; Dimovski A; Dohcev S; Stavridis S; Stankov O; Saidi S; Gjorgjievska M; Popov Z
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun; 41(1):5-14. PubMed ID: 32573479
[TBL] [Abstract][Full Text] [Related]
20. Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.
Xiao Q; Sun Y; Dobi A; Srivastava S; Wang W; Srivastava S; Ji Y; Hou J; Zhao GP; Li Y; Li H
Sci Rep; 2018 Aug; 8(1):12868. PubMed ID: 30150711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
